NIKI
Niki BioSolutions, Inc. (NIKI) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Momentum (F). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C+ (2.5) | B- (3.0) | F (0.4) | C+ (2.6) | C (2.2) |
| 2026-11-06 | C+ (2.5) | C+ (2.5) | B- (3.0) | D- (0.7) | C+ (2.7) | C (2.3) |
| 2026-10-30 | C+ (2.5) | C+ (2.5) | B- (3.0) | D- (0.7) | C+ (2.7) | C (2.3) |
| 2026-10-23 | C+ (2.5) | C+ (2.5) | B- (3.1) | F (0.6) | C+ (2.6) | C (2.3) |
| 2026-10-16 | C+ (2.5) | C+ (2.5) | B- (3.1) | D- (0.8) | C+ (2.6) | C (2.3) |